

**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 4305/1H520US1

SERIAL NO: 09/925,635

APPLICANT: Nann KRISTENSEN SONI *et al.*

FILING DATE: August 9, 2001 CONFIRMATION NO: 2913

**U.S. PATENT DOCUMENTS**

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
SF	1. 5,232,690	08/03/93	Bernhardt et al.	424	88	03/06/91

**FOREIGN PATENT DOCUMENTS**


<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION YES</u>	<u>NO</u>
SF	2. 0445710A1	03/05/91	Europe	A61K	39/39	NO	

**OTHER REFERENCES**  
**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)**\*EXAMINER INITIALS

SF

3. S. Costagliola, et al., "Recombinant Thyrotropin Receptor and the Induction of Autoimmune Thyroid Disease in BALB/c Mice: A New Animal Model," *Endocrinology* Vol. 138, No. 5, 2150-2159 (1994) (ITS-D4);
4. R.K. Gupta, et al., Adjuvant Properties of Aluminum and Calcium Compounds, M.F. Powell and M.J. Newman (Eds.), *Vaccine Design. The Subunit and Adjuvant Approach*. 1995 Plenum Press, New York, New York, pgs. 229-248;
5. J.Y. Lee, et al., "Beryllium, and Adjuvant That Promotes Gamma Interferon Production," *Infection and Immunity*, Vol. 68, No. 7, 4032-4039, XP002169720 (July 2000) (ITS-D1);
6. M.J. Newman, "Vaccines adjuvants" *Exp. Opin. Ther. Patents* 2000, 10(3):1-18;
7. D.T. O'Hagan, et al, Recent Advances in Vaccine Adjuvants: The Development of MF59 Emulsion and Polymeric Microparticles, *Mol. Med. Today* 3(2), 69-75 (February 1997);

SF



FORM PTO-1442 (REV. 7-80) U. S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

SHEET 2 OF 2  
(REV. 7-80)

### LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 4305/1H520US1

SERIAL NO: 09/925,635

APPLICANT: Nann KRISTENSEN SONI *et al.*

FILING DATE: August 9, 2001

CONFIRMATION NO: 2913

\*EXAMINER  
INITIALS

SF

8. J.K. Rao, et al., Experimental Aluminum Encephalomyelopathy. Relationship to Human Neurodegenerative Disease. Clin. Lab. Med. 18(4), 687-698 (December 1998);
9. J. Savory, et al., J. Toxicol. Environ. Health 48(6), 615-635 (30 August 1996);
10. N.F. Stas', et al., "Modification of Aluminum Hydroxide Used as an Adjuvant," Database Biosis, Khimiko-Farmatsevticheskii Zhurnal, Vol. 24, No. 7, 65-66 (1990) (ITS-D3) (Abstract);
11. F. R. Vogel and M.F. Powell, "A Compendium of Vaccine Adjuvants and Excipients" in *Vaccine Design: The Subunit and Adjuvant Approach* (Chapter 7), M.F. Powell & M.J. Newmann, Eds. (Plenum Press, New York) 1995, pp. 141-228;
12. H. Wedrychowicz, H. et al., Influence of Adjuvants on Immunity in Rabbits Vaccinated with Infective Larval Somatic Proteins of *Trichostrongylus-Colubriformis*, Database Biosis, Veterinary Parasitology, Vol. 37, No. 3-4, 273-284 (1990) (ITS-D2) (Abstract);

SF

EXAMINER:

DATE CONSIDERED:

6/13

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.